文献速递白血病淋巴瘤

Loncastuximab tesirine治疗复发/难治性B细胞急性淋巴细胞白血病

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

这项开放标签、单臂、剂量递增和扩展研究评估了抗CD19抗体药物偶联物loncastuximab tesirine在35例复发/难治性B细胞急性淋巴细胞白血病成人患者中的安全性、耐受性、药代动力学、免疫原性和初步临床活性。中位年龄55岁,中位既往治疗3线。3例患者达到完全缓解,未达到最大耐受剂量,试验因入组缓慢在剂量递增阶段终止。

要点

  • 3例患者达到完全缓解,分别见于30、120和150 μg/kg Q3W剂量组。
  • 常见治疗中出现的不良事件为恶心(42.9%)、发热性中性粒细胞减少(37.1%)和可逆性肝功能异常。
  • 未达到最大耐受剂量,未发生治疗相关死亡。

核心结论

  • Loncastuximab tesirine在复发/难治性B细胞急性淋巴细胞白血病中显示出初步临床活性,3例患者达到完全缓解。
  • 安全性总体可管理,未达到最大耐受剂量,未发生治疗相关死亡。

研究设计与样本

  • 开放标签、单臂、剂量递增和剂量扩展研究。
  • 共纳入35例复发/难治性B细胞急性淋巴细胞白血病成人患者,中位年龄55岁(范围20-80),中位既往治疗3线(范围1-15)。
  • 所有患者接受至少1次静脉输注loncastuximab tesirine,剂量15-150 μg/kg每3周一次(n=30)或50 μg/kg每周一次(n=5)。

主要发现

  • 3例患者达到完全缓解,分别见于30、120和150 μg/kg Q3W剂量组各1例。
  • 常见治疗中出现的不良事件为恶心(42.9%)、发热性中性粒细胞减少(37.1%)和可逆性肝功能异常。
  • ≥3级治疗中出现的不良事件发生于85.7%患者,最常见为发热性中性粒细胞减少及其他血液学异常和可逆性肝功能异常。
  • 4例患者(11.4%)发生2级输注相关反应;1例患者(150 μg/kg Q3W)出现剂量限制性毒性高胆红素血症,6天内消退且未采取进一步措施。
  • 药代动力学显示显著个体间变异,靶点介导的药物处置似乎贡献于时间和剂量依赖性处置;未出现临床相关的抗药抗体形成。

临床怎么用

  • 该研究为剂量探索阶段,loncastuximab tesirine在复发/难治性B细胞急性淋巴细胞白血病中的推荐剂量尚未确定。
  • 治疗期间需关注恶心、发热性中性粒细胞减少及肝功能异常等不良事件。

局限性

  • 试验因入组缓慢在剂量递增阶段终止。
  • 样本量小(35例),为单臂研究,无对照组。
  • 未达到最大耐受剂量,剂量-疗效关系尚未充分确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label, single-arm, dose-escalation, dose-expansion study assessed the safety, tolerability, pharmacokinetics (PKs), immunogenicity, and preliminary clinical activity of loncastuximab tesirine in adults with R/R B-ALL. A total of 35 patients were enrolled, with a median age of 55 years (range, 20-80) and a median of 3 prior therapies (range, 1-15). All patients received at least 1 IV infusion of loncastuximab tesirine at 15 to 150 μg/kg once every 3 weeks (Q3W; n = 30) or 50 μg/kg IV weekly (n = 5). Common treatment-emergent adverse events (TEAEs) were nausea (42.9%), febrile neutropenia (37.1%), and reversible liver test abnormalities. Grade ≥3 TEAEs were reported in 85.7% patients, most commonly febrile neutropenia and other hematologic abnormalities and reversible liver test abnormalities. There were no treatment-related deaths. Four patients (11.4%) had grade 2 infusion-related reactions, and 1 patient (150 μg/kg Q3W) had a dose-limiting toxicity of hyperbilirubinemia that resolved within 6 days without further action. The maximum tolerated dose was not reached. Three patients achieved complete responses, 1 each at 30, 120, and 150 μg/kg Q3W. PK studies showed marked interpatient variability, with target-mediated drug disposition seeming to contribute to time- and dose-dependent disposition. No clinically relevant anti-drug-antibody formation occurred. The trial was terminated in the dose-escalation phase because of slow accrual. This trial was registered at www.clinicaltrials.gov as NCT02669264.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jain N, Stock W, Zeidan A, et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020. PMID: 32012214. doi:10.1182/bloodadvances.2019000767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。